Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors

International Journal of Cancer

Volumn 124, Issue 1, 2009, Pages 150-156

  Andreasson, Kalle ^a,d   Tegerstedt, Karin ^a,b   Eriksson, Mathilda ^a   Curcio, Claudia ^c   Cavallo, Federica ^c   Forni, Guido ^c   Dalianis, Tina ^a   Ramqvist, Torbjörn ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c UNIVERSITY OF TURIN   (Italy)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Her2; Immunotherapy; Neu; Polyomavirus; Virus like particle

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOLYTIC VIRUS; TUMOR VACCINE; CANCER VACCINE; DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; MURINE PNEUMONIA VIRUS; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; RAT; TUMOR CELL LINE; TUMOR GROWTH; VIRUS LIKE AGENT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KINETICS; METABOLISM; METHODOLOGY; NEOPLASM; TRANSGENIC MOUSE;

ANIMALS; CANCER VACCINES; DNA; FEMALE; HUMANS; IMMUNOTHERAPY; KINETICS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASMS; POLYOMAVIRUS; RATS; RECEPTOR, ERBB-2;

EID: 58149375091     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23920     Document Type: Article

References (45)

1. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319: 226-30.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235: 177-82.
3. Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 2006;11:857-67.
4. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastu-zumab resistance. Breast Cancer Res 2006;8:215.
5. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5:1289-97.
6. Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003;9:5559-65.
7. Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998;188:589-96.
8. Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, Dalianis T, Kiessling R, Ramqvist T. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res 2005;65:5953-7.
9. Lindencrona JA, Preiss S, Kammertoens T, Schuler T, Piechocki M, Wei WZ, Seliger B, Blankenstein T, Kiessling R. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004;109:259-64.
10. Pupa SM, Menard S, Andreola S, Colnaghi MI. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 1993;53:5864-6.
11. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-exis- tent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000;62:245-52.
12. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89: 12180-4.
13. Salunke DM, Caspar DL, Garcea RL. Self-assembly of purified polyo-mavirus capsid protein VP1. Cell 1986;46:895-904.
14. Redmond MJ, Ijaz MK, Parker MD, Sabara MI, Dent D, Gibbons E, Babiuk LA. Assembly of recombinant rotavirus proteins into viruslike particles and assessment of vaccine potential. Vaccine 1993; 11:273-81.
15. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702.
16. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, et al. Quadrivalent vaccine against human papillomavi- rus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
17. Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I. Immune response to human papillomavi-rus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 1999;81:881-8.
18. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT. Chimeric papilloma-virus virus-like particles elicit antitumor immunity against the E7 on-coprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998;95:1800-5.
19. Pannellini T, Forni G, Musiani P. Immunobiology of her-2/neu trans-genic mice. Breast Dis 2004;20:33-42.
20. Curcio C, Khan AS, Amici A, Spadaro M, Quaglino E, Cavallo F, Forni G, Draghia-Akli R. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther 2008;15:108-14.
21. Da Silva DM, Schiller JT, Kast WM. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 2003;21:3219-27.
22. Tegerstedt K, Andreasson K, Vlastos A, Hedlund KO, Dalianis T, Ramqvist T. Murine pneumotropic virus VP1 virus-like particles (VLPs) bind to several cell types independent of sialic acid residues and do not serologically cross react with murine polyomavirus VP1 VLPs. J Gen Virol 2003;84:3443-52.
23. Piechocki MP, Pilon SA, Kelly C, Wei WZ. Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine-alanine repeat. Cell Immunol 2001;212:138-49.
24. Tegerstedt K, Franzen A, Ramqvist T, Dalianis T. Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor. Cancer Immunol Immunother 2007;56:1335-44.
25. Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133-42.
26. Nilsson SV, Magnusson G. Activities of polyomavirus large-T-anti- gen proteins expressed by mutant genes. J Virol 1984;51:768-75.
27. Mayer M, Dorries K. Nucleotide sequence and genome organization of the murine polyomavirus, Kilham strain. Virology 1991;181:469-80.
28. Chen XS, Stehle T, Harrison SC. Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry. Embo J 1998;17:3233-40.
29. Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 1998;58:1965-71.
30. Clark B, Caparros-Wanderley W, Musselwhite G, Kotecha M, Griffin BE. Immunity against both polyomavirus VP1 and a transgene product induced following intranasal delivery of VP1 pseudocapsid-DNA complexes. J Gen Virol 2001;82:2791-7.
31. Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Iezzi M, Cavallo F, Musiani P, Forni G, Monaci P. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 2005;113:67-77.
32. Vlastos A, Andreasson K, Tegerstedt K, Hollanderova D, Heidari S, Forstova J, Ramqvist T, Dalianis T. VP1 pseudocapsids, but not a glutathione-S-transferase VP1 fusion protein, prevent polyomavirus infection in a T-cell immune deficient experimental mouse model. J Med Virol 2003;70:293-300.
33. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999;223:77-92.
34. Karan D, Krieg AM, Lubaroff DM. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer 2007;121:1520-8.
35. Lubaroff DM, Karan D, Andrews MP, Acosta A, Abouassaly C, Sharma M, Krieg AM. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine 2006;24:6155-62.
36. Wilson HL, Dar A, Napper SK, Marianela Lopez A, Babiuk LA, Mut-wiri GK. Immune mechanisms and therapeutic potential of CpG oli-godeoxynucleotides. Int Rev Immunol 2006;25:183-213.
37. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ. NK-and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001;167:5247-53.
38. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleoti- des containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999;59:5429-32.
39. Yonenaga Y, Mori A, Fujimoto A, Nagayama S, Tachibana T, Ono-dera H, Uemoto S. The administration of naked plasmid DNA into the liver induces antitumor innate immunity in a murine liver metastasis model. J Gene Med 2007;9:299-307.
40. Mastini C, Becker PD, Iezzi M, Curcio C, Musiani P, Forni G, Cav-allo F, Guzman CA. Intramammary application of non-methylated- CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice. Curr Cancer Drug Targets 2008;8:230-42.
41. Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR, Schiller JT. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 2001;166:5346-55.
42. Boura E, Liebl D, Spisek R, Fric J, Marek M, Stokrova J, Holan V, Forstova J. Polyomavirus EGFP-pseudocapsids: analysis of model particles for introduction of proteins and peptides into mammalian cells. FEBS Lett 2005;579:6549-58.
43. Rolla S, Nicolo C, Malinarich S, Orsini M, Forni G, Cavallo F, Ria F. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 2006;177:7626-33.
44. Rolla S, Marchini C, Malinarich S, Quaglino E, Lanzardo S, Montani M, Iezzi M, Angeletti M, Ramadori G, Forni G, Cavallo F, Amici A. Protective immunity against neu-positive carcinomas elicited by elec-troporation of plasmids encoding decreasing fragments of rat neu extracellular domain. Hum Gene Ther 2008;19:229-40.
45. Jacob J, Radkevich O, Forni G, Zielinski J, Shim D, Jones RF, Wei WZ. Activity of DNA vaccines encoding self or heterologous Her-2/ neu in Her-2 or neu transgenic mice. Cell Immunol 2006;240:96-106.